IDH2 and glioblastoma: This retrospective cohort study suggests that the combined molecular profiling of MGMT promoter methylation and EGFR amplification may help to delineate prognostically distinct subgroups within the heterogeneous population of patients with IDH-wild-type glioblastoma (GBM).